Author:
Schuler M.,Jäger T.,Meiler J.,Gauler T.,Krege S.,Rübben H.
Publisher
Springer Berlin Heidelberg
Reference62 articles.
1. Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 21 (6): 885–897
2. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (5): 909–918
3. Barth J, Kloke M (2003) Paravasation bei Zytostatika. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie, 4. Aufl. Springer 2003, Berlin Heidelberg New York Tokio, S 1708–1715
4. Basser RL, Green MD (1994) Pulmonary toxicities. In: Kirkwood JM, Lotze MT, Yasko JM (eds) Current cancer therapeutics. Current Medicine, Philadelphia, pp 272–278
5. Bellone JD (1981) Treatment of vincristin extravasation. JAMA 245: 343